Drug Profile
Research programme: VLA-4 antagonists - Biogen Idec
Alternative Names: VLA-4 antagonists research programme - Biogen IdecLatest Information Update: 04 Mar 2009
Price :
$50
*
At a glance
- Originator Biogen Idec
- Class
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Multiple sclerosis
Most Recent Events
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 10 Jul 2002 This programme is still in active development
- 12 Oct 1999 Preclinical development for Inflammation in USA (PO)